Blog Posts

Environmental test chamber: simulate the natural environment and analyze material properties

Posted by labchamber on March 29, 2024 at 5:58am 0 Comments

Environmental test chamber: simulate the natural environment and analyze material properties



Environmental Chambers is an experimental equipment used to simulate various natural environmental conditions. It is widely used in materials science, electronic engineering, automotive industry and other fields. This article will deeply explore the principles and applications of environmental… Continue

A Step-by-Step Guide to Launching Your Own Tinder Clone App

Posted by Smith Joe on March 29, 2024 at 5:49am 0 Comments





Are you looking to create your dating app? Look no further than this step-by-step guide to launching your Tinder clone app. With the increasing popularity of online dating, making your dating app can be a lucrative…

Continue

대전, 나주, 정읍 출장마사지 서비스 탐방

Posted by QKSEO on March 29, 2024 at 5:42am 0 Comments

시간이 가장 중요하고 스트레스 수준이 높아질 수 있는 한국의 분주한 도시에서는 휴식과 활력을 되찾는 것이 무엇보다 중요합니다. 바쁜 일상 속에서 잠시 휴식을 원하는 개인에게 편리한 솔루션을 제공하는 출장 마사지 서비스가 등장하는 곳입니다. 대전, 나주, 정읍 등의 도시에서는 이러한 서비스가 지역 주민과 여행자 모두의 요구를 충족하면서 점점 인기를 얻고 있습니다 나주출장마사지.



대전: 비즈니스와 웰빙의 중심지



활기찬 비즈니스 환경과 기술 발전으로 유명한 대전은 휴식 서비스에 대한 수요가 높은 도시이기도 합니다. 분주한 기업 회의와 마감일 속에서 개인은 자신의 요구에 맞춰 이동 중에도 서비스를 제공하는 숙련된 마사지 치료사의 손에서 위안을 찾는 경우가 많습니다.



이 분야에서 눈에 띄는 선수 중 하나는 대전의 대표적인 출장 마사지 업체인 Barney입니다.… Continue

USFDA Consultants Medical Device

Posted by Aniket Chaudhari on March 29, 2024 at 5:40am 0 Comments

Medical Device Manufacturers require USFDA Approvals to sell their products in USA. USFDA differentiates product approvals in Class I, II &III depending upon the risk associated. The submissions include self-certification, 510(k) and PMA depending upon the class of the product.IZiel implements an Outcome-Based Delivery Model to provide complete solution from developing engineering documentation to receiving USFDA Approvals & establishment registrations thereafter. Our teams from USA…

Continue

The “Neoantigen Targeted Therapies Market, 2019-2030”

To order this detailed 320+ page report, please visit this link

Key Inclusions
 A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer.
 Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
 A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.
 An in-depth analysis of the various patents that have been filed / granted related to neoantigens till April 2019. It includes information on key parameters, such as patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio).
 An analysis of the various partnerships pertaining to neoantigen targeting therapies, which have been established till March 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, type of immunotherapy and the most active players.
 An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies.
 Informed estimates of the existing market size and the future opportunity for neoantigen targeted therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2019-2030.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
 Type of target disease indication
 Bone cancer
 Colorectal cancer
 Gynecological cancer
 Non-small cell lung cancer
 Renal cell carcinoma
 Other cancers

 Type of neoantigens
 Personalized neoantigens
 Off-the-shelf neoantigens

 Type of immunotherapy
 Dendritic cell vaccines
Press Release: Variation 4 (Format 5)

 DNA / RNA-based vaccines
 Protein / peptide-based vaccines
 TIL-based therapies

 Route of administration
 Intradermal
 Intravenous
 Subcutaneous
 Other routes

 Key geographical regions
 North America
 Europe
 Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held with the following experts:
 Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
 Ella Sorani (Vice President Research and Development, BioLineRx)
 Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)

To request sample pages, please visit this link

Key Questions Answered
 What are the prevalent trends related to R&D activity focused on neoantigen based therapies?
 What are the clinical conditions for which neoantigen targeted therapies are being developed?
 What are the key challenges faced by neoantigen-based therapy developed?
 Who are the leading industry and non-industry players?
 What are the key factors that are likely to influence the evolution of the neoantigen targeted therapies market?
 What are the reasons for partnership activity among stakeholders in this industry?
 Who are the key investors in neoantigen targeted therapies?
 What is share of neoantigen targeted therapies in the immunotherapy market?
 How is the current and future market opportunity likely to be distributed across key market segments and geographies?

You may also be interested in the following titles:
1. T-Cell Immunotherapies Market (4th Edition), 2019-2030
2. Novel Immuno-Oncology Biomarker Testing Market, 2019-2030
3. Companion Diagnostics Market (2nd Edition), 2019-2030

Contact Us:
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

Views: 1

Comment

You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2024   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service